Paracelsian Inc (PRLN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Berkowitz who wrote (3042)	8/8/1997 8:28:00 PM
From: Elllk	of 4342

Glaxo, which is about to lose considerable revenue now that Zantac is available in generic form, is under attack in New York State and New York City for not providing 1592U89 (Abacavir) which may have more potency and less toxicity than AZT as an AIDS treatment. Glaxo cites safety and production concerns as slowing down compassionate drug use availability and pushing for early FDA approval. Is it just coincidence that this is happening just as they are about to lose a big source of revenue? At any rate, New York State and City politicos as well as pension funds and other share holding organizations are threatening varius actions, including selling large blocks of shares if Glaxo doesn't respond. Many think 1592U89 will be the only new drug likely to be available in the near future for AIDS patients who don't respond to current treatments. Critics are pointing out that in addition to the compassionate use law President Clinton has made it possible for pharmaceutical companies to issue new AIDS drugs in 90 days with FDA approval. Does this mean if PRLN hooked up with, for instance, MRK, Androvir could be on the market in 90 or so days? Larry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next